Veradermics, Incorporated (MANE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $103.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Rich valuation.
Veradermics (MANE) is a late clinical-stage biopharma developing VDPHL01, an oral extended-release minoxidil formulation for pattern hair loss affecting approximately 80 million people in the US. The company generates no product revenue and has raised $557.8M gross including... Read more
Sell if holding. Engine safety override at $103.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.
Passes 5/6 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductVDPHL0110-K Item 1A: 'We do not expect to generate significant revenue, if any, unless and until we are able to obtain regulatory approval for, and successfully commercialize, VDPHL01'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $103.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $94.92. Score 4.7/10, moderate confidence.
Take-profit target: $112.21 (+9.9% upside). Prior stop was $94.92. Stop-loss: $94.92.
Concentration risk — Product: VDPHL01; Target reached (-10.9% upside); Quality below floor (1.6 < 4.0).
Veradermics, Incorporated trades at a P/E of N/A (forward -33.5). TrendMatrix value score: 3.0/10. Verdict: Sell.
10 analysts cover MANE with a consensus score of 4.4/5. Average price target: $107.
What does Veradermics, Incorporated do?Veradermics (MANE) is a late clinical-stage biopharma developing VDPHL01, an oral extended-release minoxidil...
Veradermics (MANE) is a late clinical-stage biopharma developing VDPHL01, an oral extended-release minoxidil formulation for pattern hair loss affecting approximately 80 million people in the US. The company generates no product revenue and has raised $557.8M gross including $294.8M from its recent IPO, with three pivotal trials underway.